ArticleActa pharmaceutica Sinica. B2025
Topical adhesive spatio-temporal nanosystem co-delivering chlorin e6 and HMGB1 inhibitor glycyrrhizic acid for
Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Complete biosynthesis of the clinical agent escin Ia.Nature communications · 2026Article
- The self-assembly mechanisms of glycyrrhizic acid: Permeation enhancement and transdermal applications.International journal of pharmaceutics: X · 2026Review
- Programmable next-generation supramolecular self-assembled materials as drug delivery systems.Bioactive materials · 2026Review
- Therapeutic potential of glycyrrhizic acid in inflammation-related diseases: from HMGB1-oriented molecular insights to preclinical application.Archives of pharmacal research · 2026Review
- Mechanisms and therapeutic potential of glycyrrhizic acid: Insights into key signaling pathways and disease modulation (Review).Molecular medicine reports · 2026Review
- Nanotechnology advances for psoriasis treatment and future prospects.Discover nano · 2026Review
- A "controlled assembly" strategy for constructingBioactive materials · 2026Article
- The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment.Frontiers in pediatrics · 2026Review
- Hypericin as a Photodynamic Immunomodulator: A Natural Compound for Dermatological Therapy.Drug design, development and therapy · 2026Review
- Microneedle Mediated Gas Delivery for Rapid Separation, Enhanced Drug Penetration, and Combined Therapy.Pharmaceutics · 2025Review
- Glycyrrhizic acid-based nanotheranostic system to enhance photothermal immunotherapy by suppressing HSP90 and remodeling tumor microenvironment.Materials today. Bio · 2025Article
- Shield microneedles loaded with biphasic-delivery liposomes modulate skin oxidation/immunity dual-axis for psoriasis therapy.Materials today. Bio · 2025Article
- Elevated SNHG15 empowers keratinocytes hyperproliferation through activation of STAT3/Cyclin D1 axis in psoriasis.Acta pharmaceutica Sinica. B · 2025Article
- Intelligent transdermal nanoparticles as synergizing advanced delivery systems for precision therapeutics.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, photodynamic therapy (PDT) has gained considerable attention as a promising therapeutic approach for the treatment of psoriasis. Unfortunately, the activation of high mobility group box 1 protein (HMGB1) by PDT triggers innate and adaptive immune responses, which exacerbate skin inflammation. Herein, we combined glycyrrhizic acid (GA), a natural anti-inflammatory compound and immunomodulator derived from the herb
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.